Protara Therapeutics Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer

Reuters

Jan 22

Protara <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer

Protara Therapeutics Inc. has announced that updated interim data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, scheduled for February 26-28, 2026, in San Francisco. The poster presentation will provide updated safety and efficacy data from approximately 25 six-month evaluable BCG-unresponsive NMIBC patients. In addition, interim safety and tolerability data from both BCG-naïve and BCG-unresponsive patients enrolled in the ADVANCED-2 trial will also be presented at the symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9630244) on January 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605499403"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605499403\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605499403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605499403","market":"fut","top_or_hot":-1,"title":"Protara Therapeutics Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Protara Therapeutics Inc. has announced that updated interim data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, scheduled for February 26-28, 2026, in San Francisco. The poster presentation will provide updated safety and efficacy data from approximately 25 six-month evaluable BCG-unresponsive NMIBC patients. In addition, interim safety and tolerability data from both BCG-naïve and BCG-unresponsive patients enrolled in the ADVANCED-2 trial will also be presented at the symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9630244) on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protara Therapeutics Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtara Therapeutics Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-22 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Protara Therapeutics Inc. has announced that updated interim data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, scheduled for February 26-28, 2026, in San Francisco. The poster presentation will provide updated safety and efficacy data from approximately 25 six-month evaluable BCG-unresponsive NMIBC patients. In addition, interim safety and tolerability data from both BCG-naïve and BCG-unresponsive patients enrolled in the ADVANCED-2 trial will also be presented at the symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9630244) on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014039.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL4Mb61b:1","article_id":"2605499403","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605499403","pubTimestamp":1769086943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protara Therapeutics Inc. has announced that updated interim data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with BCG-unresponsive non-muscle invasive bladder cancer  will be presented at the American Society of Clinical Oncology  Genitourinary Cancers Symposium, scheduled for February 26-28, 2026, in San Francisco. The poster presentation will provide updated safety and efficacy data from approximately 25 six-month evaluable BCG-unresponsive NMIBC patients. In addition, interim safety and tolerability data from both BCG-nave and BCG-unresponsive patients enrolled in the ADVANCED-2 trial will also be presented at the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","TARA":"ArTara Therapeutics, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Protara Therapeutics报告TARA-002治疗卡介苗无反应膀胱癌的最新2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TARA":0.9},"content_text":"Protara Therapeutics Reports Updated Phase 2 Data for TARA-002 in BCG-Unresponsive Bladder Cancer\n    \n\n        Protara Therapeutics Inc. has announced that updated interim data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, scheduled for February 26-28, 2026, in San Francisco. The poster presentation will provide updated safety and efficacy data from approximately 25 six-month evaluable BCG-unresponsive NMIBC patients. In addition, interim safety and tolerability data from both BCG-naïve and BCG-unresponsive patients enrolled in the ADVANCED-2 trial will also be presented at the symposium.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9630244) on January 22, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}